Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

FNCH

Finch Therapeutics Group Inc

Apr 23 • 10:22AM ET

2.42

Dollar change +0.11
Percentage change 4.76	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-47.62	Insider Own	66.31%	Shs Outstand	1.61M	Perf Week	-21.94%
Market Cap	3.90M	Forward P/E	-	EPS next Y	-	Insider Trans	-0.90%	Shs Float	0.54M	Perf Month	-5.84%
Income	-76.35M	PEG	-	EPS next Q	-	Inst Own	12.17%	Short Float	1.69%	Perf Quarter	-18.19%
Sales	0.11M	P/S	35.42	EPS this Y	-	Inst Trans	104.65%	Short Ratio	0.29	Perf Half Y	-43.06%
Book/sh	14.25	P/B	0.17	EPS next Y	-	ROA	-61.68%	Short Interest	0.01M	Perf Year	-78.99%
Cash/sh	15.60	P/C	0.16	EPS next 5Y	41.70%	ROE	-128.75%	52W Range	1.86 - 16.74	Perf YTD	-32.96%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-37.86%	ROI	-148.85%	52W High	-85.54%	Beta	0.44
Dividend TTM	-	Quick Ratio	6.33	Sales past 5Y	-16.71%	Gross Margin	-1320.56%	52W Low	30.11%	ATR (14)	0.37
Dividend Ex-Date	-	Current Ratio	6.33	EPS Y/Y TTM	33.95%	Oper. Margin	-33265.42%	RSI (14)	48.98	Volatility	25.98% 15.26%
Employees	1	Debt/Eq	1.32	Sales Y/Y TTM	-87.57%	Profit Margin	-71351.40%	Recom	1.00	Target Price	10.00
Option/Short	No / Yes	LT Debt/Eq	1.24	EPS Q/Q	88.80%	Payout	-	Rel Volume	10.40	Prev Close	2.31
Sales Surprise	-	EPS Surprise	-1377.78%	Sales Q/Q	-100.00%	Earnings	-	Avg Volume	31.31K	Price	2.42
SMA20	-1.22%	SMA50	-4.43%	SMA200	-45.68%	Trades		Volume	57,540	Change	4.76%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-09-22	Initiated	H.C. Wainwright	Buy	$17
Apr-13-21	Initiated	Jefferies	Buy	$29
Apr-13-21	Initiated	Evercore ISI	Outperform	$34
Apr-13-21	Initiated	BofA Securities	Buy	$25

Mar-25-24 09:52PM	FNCH Stock Earnings: Finch Therapeutics Gr Reported Results for Q4 2023 (InvestorPlace) +5.06%
Nov-22-23 09:14AM	Billionaire Seth Klarmans Biotech Stock Picks (Insider Monkey)
Jun-09-23 07:00AM	Finch Announces Reverse Stock Split of Common Stock (GlobeNewswire)
May-11-23 05:05AM	The Petri Dish: Laronde CEO exits after 6 months; Enanta seeks Covid pill partner (American City Business Journals) -5.06%
May-10-23 07:00AM	Finch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire) -5.95%
04:05PM	Loading…
Apr-25-23 04:05PM	Finch Therapeutics Announces Executive Leadership Transitions (GlobeNewswire) -9.94%
Apr-18-23 04:01PM	Finch Therapeutics Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Womens Hospital and Updates to University of Minnesota License Agreement (GlobeNewswire)
Mar-25-23 09:34AM	Finch Therapeutics Group Full Year 2022 Earnings: Misses Expectations (Simply Wall St.)
Mar-23-23 04:05PM	Finch Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates (GlobeNewswire)
Jan-24-23 01:53PM	Microbiome startup cuts 95% of remaining staff in 3rd layoff in 9 months (American City Business Journals)
10:55AM	Finch Therapeutics Halts Work On Its Only Clinical Stage Asset, Cuts 95% Of Workforce (Benzinga)
08:00AM	Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other Assets (GlobeNewswire)
Nov-10-22 08:15AM	Finch Therapeutics Group, Inc. (FNCH) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Finch Therapeutics Provides Corporate Updates and Reports Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-09-22 08:00AM	Finch Therapeutics to Present at the Jefferies London Healthcare Conference and Evercore ISI HealthCONx Conference (GlobeNewswire) -5.09%
08:00AM	Loading…
Oct-24-22 08:00AM	Finch Therapeutics Presents PRISM-EXT Biomarker Data at ACG 2022 and Proceeds with Patient Dosing in Phase 3 Trial of CP101 in Recurrent C. Difficile Infection (GlobeNewswire) +14.07%
Sep-05-22 12:00PM	Finch Therapeutics Group, Inc. (FNCH) Upgraded to Buy: Here's Why (Zacks)
Sep-01-22 02:23PM	After Takeda ends collaboration, microbiome startup Finch Therapeutics cuts 50 jobs (American City Business Journals)
08:00AM	Finch Therapeutics Provides Business Update (GlobeNewswire)
05:32AM	The Petri Dish: Takeda ends Finch deal, Bain buys Waltham manufacturer (American City Business Journals)
Aug-26-22 07:37AM	After Six Years Of Collaboration, Takeda Walks Away From Microbiome Drug Pact (Benzinga) -5.77%
Aug-25-22 04:30PM	Finch Therapeutics Regains Full Rights to FIN-524 and FIN-525 Targeted Microbiome Product Candidates in Development for IBD (GlobeNewswire) +8.70%
Aug-11-22 07:00AM	Finch Therapeutics Provides Corporate Updates and Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Aug-10-22 08:06AM	Here's Why We're Watching Finch Therapeutics Group's (NASDAQ:FNCH) Cash Burn Situation (Simply Wall St.) +5.26%
Jul-20-22 09:48AM	As Finch Therapeutics Group, Inc. (NASDAQ:FNCH) drops to US$103m market cap, insiders might rethink their US$650k stock purchase earlier this year (Simply Wall St.)
Jun-02-22 07:00AM	Finch Therapeutics to Participate in Upcoming June Investor Conferences (GlobeNewswire)
May-17-22 08:00AM	Finch Therapeutics to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire) +10.75%
May-16-22 07:00AM	Finch Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results (GlobeNewswire)
May-09-22 08:22AM	Finch Therapeutics to Host Corporate Update Conference Call and Webcast on May 16, 2022 (GlobeNewswire) -10.04%
Apr-29-22 12:10PM	Why Finch Therapeutics Stock Is Skyrocketing Today (Motley Fool) +20.48%
05:20PM	Loading…
Apr-28-22 05:20PM	Finch Therapeutics Announces Removal of FDA Clinical Hold on CP101 IND (GlobeNewswire) -7.49%
Apr-20-22 12:33PM	Finch Therapeutics Cuts 20% Workforce, Realigns Focus On C. Diff, Autism Programs (Benzinga) -6.28%
Apr-19-22 02:08PM	Finch cuts one-fifth of staff amid Hep B program pause (American City Business Journals)
08:30AM	Finch Therapeutics Announces Workforce Restructuring to Focus Resources on Key Development Programs (GlobeNewswire)
Mar-31-22 04:56PM	Finch Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-19-22 08:04AM	Shareholders in Finch Therapeutics Group (NASDAQ:FNCH) are in the red if they invested a year ago (Simply Wall St.)
Mar-01-22 04:30PM	Finch Therapeutics Provides an Update on its Phase 3 Trial of CP101 in Recurrent C. difficile Infection (GlobeNewswire)
Feb-23-22 07:00AM	Finch Therapeutics to Participate in the Chardan Metagenomics and Microbiome Medicines Summit (GlobeNewswire)
Feb-10-22 07:00AM	Finch Therapeutics Announces Additions to Senior Leadership Team (GlobeNewswire) -6.87%
Jan-18-22 05:38PM	First Midwest Bank Trust Division Buys Axsome Therapeutics Inc, PROSHARES TRUST, iShares ... (GuruFocus.com)
Jan-06-22 07:00AM	Finch Therapeutics Further Strengthens Patent Portfolio with Two New U.S. Patents Granted for FIN-211, an Investigational Microbiome Therapeutic in Development for Autism Spectrum Disorder (GlobeNewswire)
Jan-04-22 07:00AM	Finch Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright BioConnect Conference (GlobeNewswire)
Dec-23-21 04:38AM	Trade Alert: The Independent Director Of Finch Therapeutics Group, Inc. (NASDAQ:FNCH), Nicholas Haft, Has Just Spent US$650k Buying 1.6% More Shares (Simply Wall St.) +15.77%
Dec-20-21 07:00AM	Finch Therapeutics Appoints Joseph Vittiglio, JD, as Chief Business and Legal Officer (GlobeNewswire) +8.16%
Dec-17-21 06:31AM	We're Keeping An Eye On Finch Therapeutics Group's (NASDAQ:FNCH) Cash Burn Rate (Simply Wall St.) -8.11%
Nov-11-21 07:00AM	Finch Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.61%
Nov-10-21 07:15AM	Finch Therapeutics' C. Difficile Infection Candidate Meets Primary Goal In Mid-Stage Study (Benzinga)
07:05AM	Finch Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates (GlobeNewswire)
07:00AM	Finch Therapeutics Announces Transition of Chief Medical Officer (GlobeNewswire)
Nov-09-21 04:30PM	Finch Therapeutics Announces Positive Topline Results from PRISM-EXT Phase 2 Trial of CP101 for Prevention of Recurrent C. difficile Infection (GlobeNewswire) +5.72%
Oct-25-21 07:00AM	Finch Therapeutics Presents Positive Data from PRISM3 Clinical Trial of CP101 for Recurrent C. difficile at American College of Gastroenterology Annual Scientific Meeting (GlobeNewswire) +6.89%
Oct-18-21 08:58AM	What Type Of Shareholders Make Up Finch Therapeutics Group, Inc.'s (NASDAQ:FNCH) Share Registry? (Simply Wall St.)
Oct-12-21 07:00AM	Finch Therapeutics to Present at the Jefferies Virtual Next Generation IBD Therapeutics Summit (GlobeNewswire)
Oct-05-21 07:00AM	Finch Therapeutics Appoints Samuel Allen Hamood to its Board of Directors (GlobeNewswire)
Sep-08-21 07:00AM	Finch Therapeutics Announces the Appointment of Marc Blaustein as Chief Operating Officer (GlobeNewswire)
Sep-07-21 07:00AM	Finch Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference (GlobeNewswire)
Aug-18-21 08:54AM	Insiders might want to re-evaluate their US$42m stock purchase as Finch Therapeutics Group, Inc. (NASDAQ:FNCH) drops to US$606m (Simply Wall St.)
Aug-10-21 03:54PM	Takeda To Lead Finch-Partnered Microbiome IBD Drug (Benzinga)
07:05AM	Finch Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update (GlobeNewswire)
07:00AM	Finch Therapeutics Announces Takeda to Accelerate Leadership Role in FIN-524 Ulcerative Colitis Development Program (GlobeNewswire)
Jun-28-21 07:00AM	Finch Therapeutics Added to Russell 2000 and Russell 3000 Indexes (GlobeNewswire)
May-28-21 07:00AM	Finch Therapeutics to Present at Upcoming Virtual Investor Conferences (GlobeNewswire) -5.26%
May-13-21 07:00AM	Finch Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates (GlobeNewswire)
May-06-21 07:00AM	Finch Therapeutics to Participate in the BofA Securities 2021 Virtual Health Care Conference (GlobeNewswire)
Apr-27-21 07:00AM	Finch Therapeutics Appoints Susan E. Graf to Board of Directors (GlobeNewswire)
Mar-19-21 04:25PM	Three Biotechs, plus a Marijuana Lender, Open for Trading (Barrons.com)
Mar-18-21 10:32PM	Finch Therapeutics Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Finch Therapeutics Group, Inc. engages in the development of microbiome drugs. Its platform includes Human-First Discovery that enables reverse translation from clinical data to engineer the composition of the microbiome based on disease-modifying mechanisms. The company was founded by Mark Smith, Andrew Noh, Tom Borody and Zain Kassam in 2014 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SMISEK JEFFERY A	Director	Mar 28 '24	Sale	2.57	6,642	17,070	0	Mar 29 04:15 PM
SMISEK JEFFERY A	Director	Mar 28 '24	Sale	2.61	1,600	4,176	6,512	Mar 29 04:15 PM
SMISEK JEFFERY A	Director	Nov 22 '23	Sale	3.64	1,470	5,351	6,642	Nov 27 04:54 PM
Graf Susan E	Director	Jun 09 '23	Buy	0.27	5,010	1,353	5,010	Jun 09 04:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

FNCH

Finch Therapeutics Group Inc

Upgrade your FINVIZ experience